Fig. 4From: Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort studyEstimated cumulative incidence with discontinuation due to all adverse events (including lack of effectiveness and toxic adverse events) in the bDMARDs-naïve cases (a) and the bDMARDs-switched cases (b). ABT abatacept, ADA adalimumab, CZP certolizumab pegol, ETN etanercept, GLM golimumab, IFX infliximab, TCZ tocilizumab, TOF tofacitinib, bDMARDs biological disease-modifying antirheumatic drugsBack to article page